Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers.
Culture media composition influences patient-derived organoid ability to predict therapeutic responses in gastrointestinal cancers.
复制标题
DOI:
10.1172/jci.insight.158060
复制
发表时间:
2022-11-22
期刊:
影响因子:
8
通讯作者:
Fernandez-Zapico, Martin E.
中科院分区:
文献类型:
--
作者:
Hogenson, Tara L.;Xie, Hao;Phillips, William J.;Toruner, Merih D.;Li, Jenny J.;Horn, Isaac P.;Kennedy, Devin J.;Almada, Luciana L.;Marks, David L.;Carr, Ryan M.;Toruner, Murat;Sigafoos, Ashley N.;Koenig-Kappes, Amanda N.;Olson, Rachel L. O.;Tolosa, Ezequiel J.;Zhang, Cheng;Li, Hu;Doles, Jason D.;Bleeker, Jonathan;Barrett, Michael T.;Boyum, James H.;Kipp, Benjamin R.;Mahipal, Amit;Hubbard, Joleen M.;Hanson, Temperance J. Scheffler;Petersen, Gloria M.;Dasari, Surendra;Oberg, Ann L.;Truty, Mark J.;Graham, Rondell P.;Levy, Michael J.;Zhu, Mojun;Billadeau, Daniel D.;Adjei, Alex A.;Dusetti, Nelson;Iovanna, Juan L.;Bekaii-Saab, Tanios S.;Ma, Wen Wee;Fernandez-Zapico, Martin E.
A patient-derived organoid (PDO) platform may serve as a promising tool for translational cancer research. In this study, we evaluated PDO’s ability to predict clinical response to gastrointestinal (GI) cancers. We generated PDOs from primary and metastatic lesions of patients with GI cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma. We compared PDO response with the observed clinical response for donor patients to the same treatments. We report an approximately 80% concordance rate between PDO and donor tumor response. Importantly, we found a profound influence of culture media on PDO phenotype, where we showed a significant difference in response to standard-of-care chemotherapies, distinct morphologies, and transcriptomes between media within the same PDO cultures. While we demonstrate a high concordance rate between donor tumor and PDO, these studies also showed the important role of culture media when using PDOs to inform treatment selection and predict response across a spectrum of GI cancers. Not applicable. The Joan F. & Richard A. Abdoo Family Fund in Colorectal Cancer Research, GI Cancer program of the Mayo Clinic Cancer Center, Mayo Clinic SPORE in Pancreatic Cancer, Center of Individualized Medicine (Mayo Clinic), Department of Laboratory Medicine and Pathology (Mayo Clinic), Incyte Pharmaceuticals and Mayo Clinic Hepatobiliary SPORE, University of Minnesota-Mayo Clinic Partnership, and the Early Therapeutic program (Department of Oncology, Mayo Clinic).
登录
查看更多内容
影响因子:
7.3
作者:
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者:
Schultz N
影响因子:
64.5
作者:
Lee SH;Hu W;Matulay JT;Silva MV;Owczarek TB;Kim K;Chua CW;Barlow LJ;Kandoth C;Williams AB;Bergren SK;Pietzak EJ;Anderson CB;Benson MC;Coleman JA;Taylor BS;Abate-Shen C;McKiernan JM;Al-Ahmadie H;Solit DB;Shen MM
通讯作者:
Shen MM
影响因子:
4.6
作者:
Kumar K;Raza SS;Knab LM;Chow CR;Kwok B;Bentrem DJ;Popovic R;Ebine K;Licht JD;Munshi HG
通讯作者:
Munshi HG
影响因子:
11.2
作者:
Lenkiewicz E;Malasi S;Hogenson TL;Flores LF;Barham W;Phillips WJ;Roesler AS;Chambers KR;Rajbhandari N;Hayashi A;Antal CE;Downes M;Grandgenett PM;Hollingsworth MA;Cridebring D;Xiong Y;Lee JH;Ye Z;Yan H;Hernandez MC;Leiting JL;Evans RM;Ordog T;Truty MJ;Borad MJ;Reya T;Von Hoff DD;Fernandez-Zapico ME;Barrett MT
通讯作者:
Barrett MT
DOI:
10.1158/1078-0432.ccr-20-4116
发表时间:
2022-02-15
期刊:
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子:
--
作者:
Grossman JE;Muthuswamy L;Huang L;Akshinthala D;Perea S;Gonzalez RS;Tsai LL;Cohen J;Bockorny B;Bullock AJ;Schlechter B;Peters MLB;Conahan C;Narasimhan S;Lim C;Davis RB;Besaw R;Sawhney MS;Pleskow D;Berzin TM;Smith M;Kent TS;Callery M;Muthuswamy SK;Hidalgo M
通讯作者:
Hidalgo M